Respiratory syncytial virus, or RSV, is posing an increasing threat to older adults, with recent surges prompting health officials to closely monitor infection rates [[1], [2], [3]]. While frequently enough causing mild cold-like symptoms, RSV can lead to severe complications like pneumonia and hospitalization in this age group due to weakened immune systems and underlying health conditions [[1], [2], [3]]. The FDA’s recent approval of the first RSV vaccines for older adults marks a significant step in protecting a particularly vulnerable population, though recommendations on who should receive the vaccine are still evolving [[1]].
RSV Poses Greater Risk to Older Adults, Experts Say
Older adults face a heightened risk of severe illness from respiratory syncytial virus (RSV), a common respiratory virus that typically causes mild, cold-like symptoms, according to recent findings. This increased vulnerability is due to age-related changes in the immune system and the presence of underlying health conditions, making them more susceptible to complications like pneumonia and hospitalization.
RSV infections in older adults often present with symptoms such as fever, cough, shortness of breath, and fatigue. These symptoms can mimic those of influenza or COVID-19, leading to diagnostic challenges. The virus can also exacerbate existing chronic conditions, such as heart failure or chronic obstructive pulmonary disease (COPD).
Researchers have observed a significant increase in RSV cases among older adults in recent years. This surge is attributed to a combination of factors, including waning immunity and increased exposure following the lifting of COVID-19 restrictions. The virus spreads through close contact with infected individuals, respiratory droplets produced during coughing or sneezing, and by touching contaminated surfaces.
Currently, there are preventative measures and treatments available. In May 2023, the Food and Drug Administration (FDA) approved Arexvy, a vaccine developed by GSK, specifically for adults aged 60 and older. GSK announced the approval, marking a significant step forward in protecting this vulnerable population. Additionally, Beyfortus, a monoclonal antibody treatment from Sanofi and AstraZeneca, received FDA approval in June 2023 for infants and some older adults. Sanofi detailed the approval.
While most people recover from RSV infections with supportive care, such as rest and fluids, severe cases may require hospitalization and oxygen therapy. Antiviral medications are available but are typically reserved for high-risk individuals. Preventative measures, including frequent handwashing, avoiding close contact with sick individuals, and vaccination, are crucial in reducing the spread of RSV and protecting older adults.
Public health officials emphasize the importance of early detection and prompt medical attention for older adults experiencing RSV symptoms. The findings underscore the need for continued research and development of effective vaccines and treatments to mitigate the impact of RSV on this growing population. The availability of new preventative options offers a promising avenue for reducing the burden of RSV-related illness and hospitalization among older adults.
